Following independent data reviews on January 6 and 21, 2000, the director of the NHLBI accepted a recommendation to discontinue the doxazosin treatment arm in the BP component of the trial.

The risk of HF with reduced ejection fraction was lower among patients who received chlorthalidone than in those on amlodipine (by 22%) or doxazosin (by 36%), but no difference in risk reduction ...